Intra-Cellular Therapies. has filed a patent for pharmaceutical capsules containing lumateperone for treating diseases. The patent also covers the inclusion of additional therapeutic agents. GlobalData’s report on Intra-Cellular Therapies gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Intra-Cellular Therapies, Peptide pharmacophores was a key innovation area identified from patents. Intra-Cellular Therapies's grant share as of January 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.
The patent application (Publication Number: US20240033262A1) discloses a method for treating diseases or disorders involving or mediated by the serotonin transporter (SERT) and/or dopamine D1/D2 receptor signaling pathways. The method involves administering a pharmaceutical capsule containing lumateperone orally to a patient in need. The capsule may contain lumateperone mono-tosylate in varying amounts ranging from 1 to 30 mg of lumateperone free base, depending on the specific condition being treated.
The method outlined in the patent application covers a range of diseases and disorders, including obsessive-compulsive disorder, attention deficit disorder, attention deficit hyperactivity disorder, panic disorder, social anxiety disorder, and behavioral disturbances associated with autism. The dosage of lumateperone mono-tosylate in the capsule can be adjusted based on the specific condition being targeted, with different amounts recommended for different disorders. This method offers a potential new treatment option for patients suffering from these conditions by targeting the SERT and dopamine D1/D2 receptor signaling pathways. Further research and clinical trials may be needed to validate the efficacy and safety of this treatment approach in diverse patient populations.
To know more about GlobalData’s detailed insights on Intra-Cellular Therapies, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
